myelofibrosis: unmet needs
Published 5 years ago • 142 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
2:14
unmet needs in myelofibrosis
-
2:54
unmet needs in myelofibrosis and future outlooks
-
1:30
addressing unmet needs in myelofibrosis: alleviating anemia
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
2:12
the current challenges and unmet needs in myelofibrosis: clinical practice and trials
-
3:52
optimizing the selection between available jak inhibitors in myelofibrosis
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
3:30
unmet needs in mf: managing anemia & improving the efficacy of first and second-line treatments
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
2:44
myelofibrosis: jenson shares his experience
-
14:40
primary myelofibrosis (pmf)
-
2:12
navtemadlin and its role in the treatment of r/r myelofibrosis
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:05
unmet needs in gvhd & the promise of regenerative medicine
-
1:52
phase i dose-escalation study of the bet inhibitor incb057643 in r/r myelofibrosis
-
1:58
current barriers to early intervention in myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:13
splicing mutations in post-et/post-pv myelofibrosis